RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. Pharmaceutics 2021, 13, 330
- PMID: 37376227
- PMCID: PMC10301172
- DOI: 10.3390/pharmaceutics15061623
RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. Pharmaceutics 2021, 13, 330
Abstract
The authors and the journal retract the article, 'Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation' [...].
Retraction of
-
Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation.Pharmaceutics. 2021 Mar 4;13(3):330. doi: 10.3390/pharmaceutics13030330. Pharmaceutics. 2021. Retraction in: Pharmaceutics. 2023 May 30;15(6):1623. doi: 10.3390/pharmaceutics15061623. PMID: 33806415 Free PMC article. Retracted.
References
Publication types
LinkOut - more resources
Full Text Sources
